Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 26, 2023

Survival Outcomes in Patients With HR+ MBC With Low or No HER2 Expression Treated With Targeted Therapies Plus Endocrine Therapy

JAMA Network Open

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Network Open
Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy
JAMA Netw Open 2023 May 01;6(5)e2313017, JA Mouabbi, A Singareeka Raghavendra, RL Bassett, A Hassan, D Tripathy, RM Layman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading